Navigation Links
Effectively Influencing the Hospital Marketplace to Win a Place on Formularies
Date:4/1/2008

CHAPEL HILL, N.C., April 1, 2008 /PRNewswire/ -- Faced with shrinking staffs and less physician availability, pharmaceutical sales forces are having a challenging time serving the hospital marketplace. As their time to communicate with physicians continues to shrink, sales reps for the pharma industry are turning to other decision-makers in the hospital market to win a place on formularies, according to research from benchmarking leader Best Practices, LLC.

The study provides strategic insight into the optimal sales strategy, structure and resources for influencing the hospital market. Review a complimentary excerpt of the study at http://www3.best-in-class.com/rr922.htm.

Among hospital administrative personnel, pharmacy and therapeutic committee members are the key formulary decision-makers for both hospital networks and local hospitals, according to the study. Likewise, best-in-class companies don't view it as effective to target senior administrative decision- makers such as CEOs and COOs at hospital networks, the research found.

Additionally, the 66-page report, Sales Force Effectiveness: Benchmarking the Resources and Structure Required to Service the U.S. Hospital Marketplace, found that 80 percent of companies focus additional sales force training on hospital system networks to help their sales forces navigate the decision- making structure of hospital networks.

The research encompasses all the key hospital market segments, from community hospitals to Academic Medical Centers. Companies that participated in the study and shared their hospital sales force strategies include: Bayer, Eli Lilly, AstraZeneca, Novartis, GlaxoSmithKline, Johnson & Johnson and Pfizer.
The study's key focus areas include:

-- Targeting Key Decision Makers/Influencers in Making Formulary

Decisions

-- Hospital Sales Force Alignment, Structure and Support

-- Hospital Sales Force Staffing and Training

-- Group Purchasing Organization Targeting and Sales Force Size

To learn more about this report, including information about the research participants, key findings and sample best practices, please download a complimentary excerpt and study overview at http://www3.best-in-class.com/rr922.htm .

For questions or additional information on Best Practices, LLC's other products and services, please call Cameron Tew at 919-767-9246 or email ctew@best-in-class.com. Also, visit our Web site at http://www.best-in-class.com/ .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call 919-403-0251 or visit http://www3.best-in-class.com/.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. How to effectively avoid many common complications and liver damage in bile duct exploration?
2. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
3. New therapy effectively treats deep vein thrombosis
4. Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer
5. Generous Donors Allow Red Cross to Respond Swiftly and Effectively to California Wildfires
6. Radiation seeds effectively cure prostate cancer in young men
7. Tiny radioactive spheres effectively treat cancer that has spread to the liver
8. Study finds multiple neglected tropical diseases effectively treated with drugs
9. Can racial health disparities be effectively reduced?
10. T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... Robert E. Burke, MD, PhD, had a successful career as a pediatrician ... could have led him down a much different path. , In his book, “Beyond ... Pediatrics,” Dr. Burke shares a personal account of the tribulations he encountered on his ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long ... company involved in the underground testing of nuclear weapons. Years later, when her co-workers ... of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... transplant clinic serving San Francisco and environs, is proud to announce an upgrade ... research information on the upgraded Yelp page on topics as diverse as Platelet ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology: